$JNJ (Johnson & Johnson)

$JNJ {{ '2016-09-12T18:38:31+0000' | timeago}} • Announcement

Healthcare company $JNJ said that Janssen Vaccines & Prevention BV has completed a submission to the WHO for Emergency Use Assessment and Listing (EUAL) for its investigational preventive Ebola prime-boost vaccine regimen. The EUAL can be implemented when there is a disease outbreak with high mortality rates and a lack of treatment options.

$JNJ {{ '2017-09-22T21:34:55+0000' | timeago}} • Announcement

$JNJ said Janssen Biotech, Inc. received a complete response letter from the US FDA for the Biologics License Application (BLA) seeking approval of sirukumab for the treatment of moderately to severely active rheumatoid arthritis. The letter states that additional clinical data are needed to further evaluate the safety of sirukumab.

$PFE {{ '2017-09-20T18:14:48+0000' | timeago}} • Announcement

$PFE filed a lawsuit against $JNJ over anticompetitive practices. The lawsuit alleges J&J violated federal antitrust laws by signing exclusionary contracts with health insurers, hospitals and doctor groups to ensure its medicine Remicade was given preferential treatment over Pfizer's new biosimilar Inflectra.

$JNJ {{ '2017-09-06T18:27:40+0000' | timeago}} • Announcement

Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of $JNJ, received FDA approval for a new 32 mg tablet for oral suspension for TRACLEER for use in pediatric patients aged three years and older, suffering from high blood pressure in the arteries of the lungs. The medication will be available from 4Q17.

$JNJ {{ '2017-08-28T15:56:47+0000' | timeago}} • Announcement

$JNJ said results from a Phase 3 study found that the XARELTO plus aspirin 100 mg once daily significantly reduced the risk of major cardiovascular (CV) events including CV death, heart attack or stroke by 24% in patients with stable coronary and/or peripheral artery disease, compared to aspirin alone. The study was conducted on 27,395 patients.

$JNJ {{ '2017-07-24T17:21:48+0000' | timeago}} • Announcement

$JNJ said preliminary data from a phase 1/2a clinical trial on an investigational HIV-1 vaccine regimen showed positive results in a sample of 393 healthy volunteers. If the vaccine clears the phase 3 trials, its launch can be expected within a decade. There are currently around 37MM AIDS patients around the world.

$JNJ {{ '2017-07-18T19:50:54+0000' | timeago}} • Webcast

$JNJ expects that the growth acceleration in the back half of 2017 will create some momentum going into 2018, as the majority of growth acceleration in both Hospital Medical Devices and Consumer have to do with new product launches. However, the company said it is not prepared to talk about guidance.

$JNJ {{ '2017-07-18T19:30:46+0000' | timeago}} • Webcast

$JNJ CEO Alex Gorsky said during the conference call, "We remain very optimistic about Pharma in the second half of the year and we continue to see really strong uptake both with DARZALEX and the various multiple myeloma indications earlier utilization."

$JNJ {{ '2017-07-18T18:58:31+0000' | timeago}} • Webcast

$JNJ said it has a pipeline of more than 10 new blockbuster products to launch or file for regulatory approval in the next five years, each with greater than $1Bil in peak year sales potential.

$JNJ {{ '2017-07-18T11:59:48+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphics: Q2 2017 highlights

$JNJ {{ '2017-07-18T11:26:59+0000' | timeago}} • Announcement

Medical Devices segment was the top performer for $JNJ in 2Q17, with a growth of 4.9%. While Consumer segment added to this with a 1.7% growth, Pharmaceutical segment edged down 0.2%.

$JNJ {{ '2017-07-18T11:19:55+0000' | timeago}} • Announcement

$JNJ CEO Alex Gorsky said, "Our pharmaceutical pipeline continued its strong momentum with the approval of TREMFYA as well as the submission and approval of several key line extensions. We are optimistic that the investments we are making will accelerate our sales growth in the second half of this year."

$JNJ {{ '2017-07-18T11:14:25+0000' | timeago}} • Announcement

$JNJ, which recently acquired Actelion Ltd for $30Bil, raised its sales guidance for FY17 to $75.8-76.1Bil. Additionally, the New Brunswick, NJ - based company raised its adjusted earnings guidance for the same period to $7.12-7.22 per share.

$JNJ {{ '2017-07-18T11:08:14+0000' | timeago}} • Announcement

Pharmaceutical giant $JNJ reported growth in sales and adjusted EPS in 2Q17. While sales increased 2% to $18.8Bil riding on International sales growth of 2.3%, adjusted EPS stood at $1.83, representing an increase of 3.1%. On a GAAP basis, net earnings were down to $3.8Bil, or $1.40 per share, compared to $4Bil, or $1.43 per share, a year ago.

$JNJ {{ '2017-07-17T15:58:16+0000' | timeago}} • Announcement

$JNJ has declared a cash dividend for 3Q17 of $0.84 per share on its common stock. The dividend is payable on September 12, 2017 to shareholders of record as on August 29, 2017. The ex-dividend date is August 25, 2017.

$JNJ {{ '2017-06-27T15:40:39+0000' | timeago}} • Announcement

DePuy Synthes Products, part of the $JNJ, acquired Innovative Surgical Solutions LLC, doing business as Sentio LLC, a privately-held company based in Wixom, Michigan that markets innovative nerve localization technology for spine surgery. Financial terms of the transaction have not been disclosed.

$JNJ {{ '2017-06-16T19:49:20+0000' | timeago}} • Announcement

Janssen Biotech, a $JNJ company, said FDA has approved immunotherapy Darzalex in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior commonly used therapies. Multiple myeloma is incurable blood cancer that starts in the bone marrow's plasma cells.

$JNJ {{ '2017-06-16T11:31:37+0000' | timeago}} • Announcement

$JNJ expects acquisition of Actelion to add approx $1.3Bil in sales for 2017 and be accretive to 2017 adjusted EPS by approx $0.07. This impact was already included in the company's full-year guidance provided in April. Also, in the first full year after close, $JNJ expects the transaction to add to adjusted EPS by $0.35 to $0.40.

$JNJ {{ '2017-06-16T11:28:17+0000' | timeago}} • Announcement

Upon completion of $JNJ's public tender offer, Actelion has spun off its drug discovery operations assets into a newly created Swiss biopharmaceutical company, Idorsia Ltd. Shares of Idorsia were distributed to Actelion’s shareholders as a stock dividend. A $JNJ unit will initially hold 9.9% of the shares of Idorsia.

$JNJ {{ '2017-06-16T11:23:40+0000' | timeago}} • Announcement

$JNJ has completed the acquisition of Actelion Ltd for about $30Bil in cash. The acquisition was completed through a public tender offer by $JNJ unit Janssen Holding GmbH, to acquire all publicly held shares of Actelion Ltd for $280 per share. Actelion will now become part of the Janssen Pharmaceutical Companies.

$JNJ {{ '2017-06-14T13:47:21+0000' | timeago}} • Announcement

Janssen Pharmaceuticals, a $JNJ company, announced results from the Phase 2b Topaz Trial which demonstrated that treatment with pimodivir significantly decreased viral load over seven days versus placebo, in adult patients with acute, uncomplicated seasonal influenza A.

Recent Transcripts

IMUC (ImmunoCellular Therapeutics, Ltd.)
Wednesday, August 23 2017 - 9:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
VCEL (Vericel Corporation)
Wednesday, August 9 2017 - 12:00pm
NKTR (Nektar Therapeutics)
Tuesday, August 8 2017 - 9:00pm
DRRX (DURECT Corporation)
Tuesday, August 8 2017 - 8:30pm
ZTS (Zoetis Inc.)
Tuesday, August 8 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
CYTK (Cytokinetics, Incorporated)
Wednesday, August 2 2017 - 8:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, July 28 2017 - 12:30pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, July 26 2017 - 12:30pm
ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
DRRX (DURECT Corporation)
Wednesday, May 10 2017 - 8:30pm

AlphaGraphics you may like